Nutlin-3a

Catalog No.S8059 Synonyms: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 10 Publications

7 Customer Reviews

  • Nutlin-3a preserved p53 expression without influencing high glucose (HG)-induced podocyte impairment. A-D: cultured podocytes were pre-treated by nutlin-3a for 2 hrs before subjected to HG treatment. Western blotting gel documents (A) and summarized data (B) showing the expression of p53 and MDM2 in podocytes under HG exposure for 24 hrs. n = 4. Western blotting gel documents (C) and summarized data (D) showing the expression of Desmin in podocytes under HG exposure for 24 hrs. n = 3. *P < 0.05 vs. Ctrl, #P < 0.05 vs. Vehl + HG. Ctrl: control; Vehl: vehicle; nutlin-3a: nutlin-3a treatment.

    J Cell Mol Med, 2017, 21(12):3435-3444. Nutlin-3a purchased from Selleck.

    Twenty-four hours after plating 1×105 Shh-EGFP cells, media was changed to serum-free media containing vehicle, 8µM Nutlin-3a, and/or Shh (3µg/mL). Cells were also transduced with lentivirus containing pLKO.1 empty vector or LentiORF-YFP-WIP1. 48 hours later, cells were fixed in 4% paraformaldehyde, permeabilized, incubated with α-WIP1 or α-Ki-67 antibody, and mounted using media containing DAPI. Scale bar, 100µm.

    Oncogene, 2016, 35(42):5552-5564. Nutlin-3a purchased from Selleck.

  • (a) Westernblot analysis of the whole cell lysate from WT-MTEC, KO-MTEC and 1601 treated with or without Nutlin-3a (15 μM for MTEC) with antibodies as indicated.

    Int J Cancer. 2019, 144(4):777-787. Nutlin-3a purchased from Selleck.

    Protein expression of p53, TAZ and CYP24A1 were detected by western blot after treatment with Nutlin 3a in CCLP-1.

    Cancer Lett, 2016, 381(2):370-9. Nutlin-3a purchased from Selleck.

  • Assessment of cell viability with WST1 tetrazolium salt assays in TP53 WT and KO isogenic cell lines after exposure to Nutlin-3a.

    Br J Haematol, 2017, 177(1):80-94. Nutlin-3a purchased from Selleck.

    C) Control-threated cells show an strong nuclear expression of MDM2 and predominantly cytoplasmic localization of FOXM1. D) After treatment with nutlin-3a, the MDM2 immunoreactivity shifted to the perinuclear space indicating a de novo 952 MDM2 synthesis as result of increased p53 activity. In those cells, FOXM1 expression is lost due to p53 activation.

    Neuroendocrinology, 2018, 107(1):1-23. Nutlin-3a purchased from Selleck.

  • Protein expression of TP53 and p21 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated. C, untreated control; *, cancer cell lines carrying TP53 mutation. Het, heterozygous TP53 mutation; hom, homozygous TP53 mutation.

    PLoS One, 2015, 10(8):e0135101.. Nutlin-3a purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NV36epdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjDXHJEUUN3ME2wMlYyOjN5IN88US=> NEnQW5NUSU6JRWK=
H4 M4TWdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjnNVhDUUN3ME2wMlY3OjhizszN MULTRW5ITVJ?
PA-1 NFfCfVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPXTWM2OD1yLki3NFk3KM7:TR?= M3TTenNCVkeHUh?=
NKM-1 NYPzdGFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XCe2lEPTB;MT6wOFk{OSEQvF2= Ml7kV2FPT0WU
NEC8 M{jiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTFwMkG1O|Ih|ryP M3LORnNCVkeHUh?=
EoL-1-cell MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTFwMk[3NFEh|ryP NV;qNYNIW0GQR1XS
K5 NELET|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWraWYNvUUN3ME2xMlQzODd{IN88US=> NHfSVVJUSU6JRWK=
QIMR-WIL Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILsbWFKSzVyPUGuOlA5PTRizszN NX\PTFM4W0GQR1XS
MOLT-16 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvtTWM2OD1zLke4OlA1KM7:TR?= NV6x[21nW0GQR1XS
CHP-212 NV3tNot7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\mSHpKSzVyPUGuPFE{PjlizszN M3HVb3NCVkeHUh?=
CTB-1 MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m1XWlEPTB;Mj6wNlI1PiEQvF2= MXzTRW5ITVJ?
MOLT-4 M2O1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTJwM{K4OVMh|ryP NFHWe|BUSU6JRWK=
A101D MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUX1UpBuUUN3ME2yMlM2ODFizszN NHy4OWhUSU6JRWK=
DOHH-2 M1niNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nNfmlEPTB;Mj60NlI4QSEQvF2= NXnocGdNW0GQR1XS
ES4 NHvrdphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHjclBKSzVyPUKuOFMyPTVizszN NWr1cIE3W0GQR1XS
SW780 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LkTGlEPTB;Mj61NFg5OyEQvF2= M2\QdHNCVkeHUh?=
VA-ES-BJ NXvXO25PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\SfGlEPTB;Mj61OFEyKM7:TR?= MWjTRW5ITVJ?
RPMI-8866 MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37aVmlEPTB;Mj61OlIyPCEQvF2= MkTDV2FPT0WU
ML-2 NYXjRoduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NECzN5ZKSzVyPUKuOVY2PzZizszN M2jKOHNCVkeHUh?=
MSTO-211H NEXo[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;GO4tvUUN3ME2yMlU4PDVzIN88US=> NXPrS3JQW0GQR1XS
JVM-3 M37Z[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTZTWM2OD1{LkW5N|I1KM7:TR?= M1vIdHNCVkeHUh?=
A3-KAW NWOxXZJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzSTWM2OD1{Lk[xPFE5KM7:TR?= Ml7nV2FPT0WU
DK-MG Mkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTJwNkK0O|Eh|ryP NH\RXWZUSU6JRWK=
LNCaP-Clone-FGC NXTJWWJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGH3cZdKSzVyPUKuOlQ{OThizszN NFjBSGRUSU6JRWK=
HT-144 M{TjSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJwNkS1O|ch|ryP M1vTN3NCVkeHUh?=
NB69 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEO2dmdKSzVyPUKuOlU{OzRizszN MnuzV2FPT0WU
A172 M{Tp[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJwNke1PFgh|ryP NYKwO4dTW0GQR1XS
RS4-11 M1:wWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3y0RmlEPTB;Mj63NlQxPyEQvF2= MoH4V2FPT0WU
DU-4475 NXPoUIhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3NTWM2OD1{Lke5OVAzKM7:TR?= NXnENHZUW0GQR1XS
SJSA-1 M13Demdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf4TWM2OD1{LkiyOVU3KM7:TR?= MkPYV2FPT0WU
BV-173 M2f4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XZNGlEPTB;Mj64OFQ{QSEQvF2= NULlfGZMW0GQR1XS
U-2-OS MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7SVVRKSzVyPUKuPVExPyEQvF2= MkHmV2FPT0WU
CHP-134 NUG1e5N1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJwOUO4PFIh|ryP MXPTRW5ITVJ?
D-502MG NGK4ZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJwOUexOVQh|ryP MmLwV2FPT0WU
KS-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHiWIRwUUN3ME2zMlAyPjJ|IN88US=> MnnlV2FPT0WU
A204 NV\iSXZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDWUldKSzVyPUOuNFU2QDhizszN Mn\NV2FPT0WU
KGN NFfWVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDKTWM2OD1|LkC4OFk3KM7:TR?= NIqwTGhUSU6JRWK=
NCI-H292 NYfH[ph3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PZNmlEPTB;Mz6xNlAzQCEQvF2= MVjTRW5ITVJ?
CAKI-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjXW49KSzVyPUOuNVI3QTRizszN M4fVeXNCVkeHUh?=
C2BBe1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XHZ2lEPTB;Mz6xO|AzPiEQvF2= NUW1flZYW0GQR1XS
NB10 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTNwMkC5OlYh|ryP NGfiNIxUSU6JRWK=
MHH-NB-11 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjud|JKSzVyPUOuNlY5OjdizszN M2PhNXNCVkeHUh?=
NCI-SNU-1 NGDQO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rmSmlEPTB;Mz6yO|g1OyEQvF2= M4ixSnNCVkeHUh?=
HCT-116 Mk[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHCTWM2OD1|LkOwN|M2KM7:TR?= MXjTRW5ITVJ?
G-401 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPmbmhKSzVyPUOuN|Y{OjJizszN NWT0eIl4W0GQR1XS
MN-60 NFzQdIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzTW457UUN3ME2zMlQ1ODl{IN88US=> NVfYN2RLW0GQR1XS
SW982 M3vzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXhfFVKSzVyPUOuOVA5PDhizszN MnfqV2FPT0WU
RKO MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rGSGlEPTB;Mz61N|k{PiEQvF2= Mk\hV2FPT0WU
D-283MED NH;VbXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvzd|BKSzVyPUOuOVc6QDZizszN MUHTRW5ITVJ?
LB996-RCC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TadGlEPTB;Mz62NlU2QCEQvF2= MV3TRW5ITVJ?
A549 NFT3dJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfJPXVKSzVyPUOuOlM2PTJizszN MYrTRW5ITVJ?
LB2241-RCC NWHIOm9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7xTWM2OD1|Lk[1O|A5KM7:TR?= NXu0fmQ3W0GQR1XS
SK-HEP-1 NIPJSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jaVmlEPTB;Mz63OFI6PyEQvF2= Mn\HV2FPT0WU
G-402 M1XHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIOwcYxKSzVyPUOuPFA5OzJizszN NV\HSHA1W0GQR1XS
GOTO Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTNwOESzN|Mh|ryP MUXTRW5ITVJ?
LOXIMVI Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV35bZQ2UUN3ME2zMlg2Pjd3IN88US=> NXPLUGpiW0GQR1XS
NH-12 NH\5XFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofDTWM2OD12LkCxPVU6KM7:TR?= M1jYZ3NCVkeHUh?=
CTV-1 NHjJZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXDdXozUUN3ME20MlA4QTd|IN88US=> MUPTRW5ITVJ?
CP50-MEL-B NHnpR|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjSTWM2OD12LkK0N|kzKM7:TR?= NIHWOZpUSU6JRWK=
RH-18 Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnE[|VGUUN3ME20MlI4PzB4IN88US=> NUfvXXE6W0GQR1XS
NB17 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPiTWM2OD12LkOxO|Y5KM7:TR?= Ml3BV2FPT0WU
A375 NInrTpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3mTWM2OD12LkOzOVI1KM7:TR?= M{PaTHNCVkeHUh?=
IST-MES1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGH5bVRKSzVyPUSuOFE1OTFizszN MUTTRW5ITVJ?
MZ2-MEL MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPUTWM2OD12LkWwNVU2KM7:TR?= NX3YcGw1W0GQR1XS
CAL-54 NYW5Rok{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjTS4hKSzVyPUSuOVMxOTlizszN Mo[4V2FPT0WU
NCI-H28 MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTRwNkK3NVch|ryP Mkm2V2FPT0WU
D-247MG M1fJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnn3TWM2OD12Lke1NFczKM7:TR?= M376ZXNCVkeHUh?=
NCI-H460 Mn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnyTWM2OD12LkmxNVI4KM7:TR?= MUXTRW5ITVJ?
MCF7 MmruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDCVIhKSzVyPUWuOFQzPDRizszN MkTzV2FPT0WU
697 M4j4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTVwNES1OUDPxE1? MX3TRW5ITVJ?
ONS-76 NX3ZR|ljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlGzTWM2OD13LkW3NFA6KM7:TR?= NED4SmlUSU6JRWK=
C32 MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXZTWM2OD13Lk[wNFI6KM7:TR?= M{DnXnNCVkeHUh?=
OS-RC-2 M3HVSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHVdVFLUUN3ME21Mlc{QDh5IN88US=> NFv6[ZRUSU6JRWK=
MEL-HO MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nwT2lEPTB;NT64OVY3PyEQvF2= NHfXXoFUSU6JRWK=
LoVo MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTZwMEG2NlQh|ryP M3:4cXNCVkeHUh?=
AGS MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTZwMUS4Nlgh|ryP Mke5V2FPT0WU
GI-ME-N NEGxbXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvYTWM2OD14LkKyOFIyKM7:TR?= MlqwV2FPT0WU
H-EMC-SS MnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW4TWM2OD14LkO4OkDPxE1? M37GNnNCVkeHUh?=
RVH-421 M2HzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXCVllIUUN3ME22MlQzPDJ6IN88US=> MkW0V2FPT0WU
SW954 M4DlOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLzfnJyUUN3ME22MlU2PTd{IN88US=> NYfsbmFvW0GQR1XS
NB5 M3TxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTZwNU[xPFMh|ryP MWTTRW5ITVJ?
NCI-H2122 NUi3cXBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mly3TWM2OD14LkW4O|k{KM7:TR?= NWTWOY51W0GQR1XS
AM-38 M3XUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPLW4dKSzVyPU[uO|U3OzlizszN MljpV2FPT0WU
KNS-81-FD MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTZwN{[0PVQh|ryP MoPuV2FPT0WU
LS-513 NV:yPGJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nFPWlEPTB;Nj63PVAzPiEQvF2= NYL5cZNuW0GQR1XS
A427 Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;zbGhKSzVyPU[uPFc5OjlizszN MVLTRW5ITVJ?
WM-115 NVewcmJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfpZZZKSzVyPU[uPVMzOyEQvF2= MXnTRW5ITVJ?
COLO-829 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPDXmlKSzVyPUeuNlQyQDhizszN Mn73V2FPT0WU
NCI-H1650 NG\TendIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLUeo5KSzVyPUeuN|kzOjhizszN NGPTcZRUSU6JRWK=
NCI-H358 M3rSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTtSox4UUN3ME23MlQ1QDd7IN88US=> M1XzV3NCVkeHUh?=
HT-1080 NXnCRY93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{ixXGlEPTB;Nz60PFI2PCEQvF2= NGjHWXZUSU6JRWK=
HCC2218 NH\nXnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTdwNkK5O{DPxE1? Mn3aV2FPT0WU
NCI-H661 M1juUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYe4S3d{UUN3ME23Mlg4ODZ7IN88US=> MUXTRW5ITVJ?
KM-H2 MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;LTWM2OD15Lki4Olk1KM7:TR?= MXLTRW5ITVJ?
RPMI-2650 NGTSeW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkKzTWM2OD15Lkm0OFE1KM7:TR?= MV\TRW5ITVJ?
NCI-H226 NHqyXWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRThwMkGxNlIh|ryP MWjTRW5ITVJ?
MKN45 NIfkfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvCT4Y1UUN3ME24MlI3PjB{IN88US=> MUHTRW5ITVJ?
D-392MG M2XqdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRThwNUK3NlIh|ryP NWLZW|Z3W0GQR1XS
RCC10RGB MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LFcGlEPTB;OD64OlY6PSEQvF2= MlHEV2FPT0WU
CAL-51 M33jR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIS2Ro5KSzVyPUmuNVAzPTFizszN M1\TTnNCVkeHUh?=
COLO-678 M4Tlb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrQeJVJUUN3ME25MlMzQDFzIN88US=> MYXTRW5ITVJ?
SK-MEL-24 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofvTWM2OD17LkW1PFU3KM7:TR?= NGn1WZFUSU6JRWK=
SK-MEL-30 MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTlwOUS0O|Yh|ryP MkLmV2FPT0WU
MMAC-SF M1nDWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHjOHdKSzVyPUGwMlM6PjFizszN M37kSnNCVkeHUh?=
NTERA-S-cl-D1 MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTFyLk[1NFgh|ryP NXqxcJVoW0GQR1XS
NB12 NXy5NZpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLnZYZKSzVyPUGxMlUxOyEQvF2= NXX2bW8yW0GQR1XS
UACC-257 NF;odIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfkUoM2UUN3ME2xNU45Pjl3IN88US=> M1PDR3NCVkeHUh?=
LAN-6 M{K0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXoe3dKSzVyPUGxMlk6OjhizszN NFi0ZYZUSU6JRWK=
SW1573 M{K2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\lS2lEPTB;MUKuN|A5PiEQvF2= M4TVdnNCVkeHUh?=
NMC-G1 NWrxN5R[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnmT4RpUUN3ME2xNk41OTd3IN88US=> MYfTRW5ITVJ?
SHP-77 NXe4T29RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TlWGlEPTB;MUKuOVU4PCEQvF2= MUDTRW5ITVJ?
IGROV-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrxTWM2OD1zMj62OVc{KM7:TR?= Mly0V2FPT0WU
22RV1 Ml;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M333emlEPTB;MUKuPFA2QSEQvF2= NF3BfY1USU6JRWK=
SK-MEL-3 NXjjTHRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTF|LkO5O|Mh|ryP M33Xd3NCVkeHUh?=
NCI-H1563 NGK4d5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:3ZWRKSzVyPUGzMlQzODJizszN MXTTRW5ITVJ?
IGR-1 NHnWeZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTF2LkCzOFch|ryP NHrYVXlUSU6JRWK=
EW-3 NVi0N3ppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1uzdGlEPTB;MUSuNVY{QSEQvF2= NIXteWZUSU6JRWK=
JEG-3 M4i4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoniTWM2OD1zND60PVU{KM7:TR?= NF3jUZNUSU6JRWK=
ES3 NHzYTnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnFepJKSzVyPUG0MlY2PjJizszN Mn\rV2FPT0WU
MDA-MB-175-VII MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLSd3RKSzVyPUG0MlcyOTFizszN NGLFcIVUSU6JRWK=
P30-OHK M3\TcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7xSnNGUUN3ME2xOU4xPDl4IN88US=> MmOxV2FPT0WU
GP5d MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPpTWM2OD1zNT6xOFY3KM7:TR?= MkLVV2FPT0WU
HMV-II MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUT6WpRzUUN3ME2xOU4{OzN|IN88US=> M4O0fHNCVkeHUh?=
COLO-679 M3nLOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjhTWM2OD1zNT61NFEh|ryP MoXYV2FPT0WU
JAR NHvxfIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHiNpZDUUN3ME2xOU44OjB3IN88US=> Ml;zV2FPT0WU
NCI-H1666 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mli0TWM2OD1zNT65N|k6KM7:TR?= MnTOV2FPT0WU
SW48 MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\DSXJKSzVyPUG1Mlk2OTZizszN Moq0V2FPT0WU
NCI-H720 M3TqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHFS|hKSzVyPUG1Mlk6QDlizszN MnHDV2FPT0WU
HT-1197 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;DdYlKSzVyPUG2MlA{PTJizszN MmXMV2FPT0WU
HL-60 MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTF4LkCzPFQh|ryP M33Gc3NCVkeHUh?=
BEN M13idGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7kTWM2OD1zNj61OlM5KM7:TR?= M{G3cHNCVkeHUh?=
HAL-01 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFn0VoNKSzVyPUG2Mlg6ODlizszN MmK5V2FPT0WU
SW900 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXINohjUUN3ME2xOk46OTN{IN88US=> MWDTRW5ITVJ?
SBC-1 NX7qc4dNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[2TWM2OD1zNz61OFI6KM7:TR?= NGXCbmFUSU6JRWK=
SH-4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LyOWlEPTB;MUeuOVg1OSEQvF2= NHnLW2pUSU6JRWK=
UACC-62 NFnSR5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGizOZZKSzVyPUG3Mlc3OzdizszN NUSzflVGW0GQR1XS
BHT-101 MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVS1eZdmUUN3ME2xPU45PzB3IN88US=> NFnxZ3BUSU6JRWK=
DB M{DrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUWxbFVxUUN3ME2yNU42PjR7IN88US=> MX\TRW5ITVJ?
SK-MEL-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG4N5hKSzVyPUKxMlU5PzJizszN NXfoWIpmW0GQR1XS
NCI-H747 MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3vTWM2OD1{Mj63N|c6KM7:TR?= M1r4PHNCVkeHUh?=
SK-LU-1 NEP5VGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJ|LkO1NlQh|ryP MYjTRW5ITVJ?
KG-1 NF\Zc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\PN2pKSzVyPUKzMlQ6PDZizszN MnS1V2FPT0WU
LXF-289 NV7TbXZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorUTWM2OD1{Mz63NVQh|ryP NVHMVpRrW0GQR1XS
HCC1954 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXwTWM2OD1{ND64PFQ1KM7:TR?= MXXTRW5ITVJ?
Ramos-2G6-4C10 NFn6bmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\pTmlEPTB;Mk[uOFk5OSEQvF2= NUi4bYp6W0GQR1XS
DBTRG-05MG MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJ4Lk[0PFgh|ryP M4\ZPHNCVkeHUh?=
NCI-H2052 NIizNJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJ5LkW2PFQh|ryP NVnWd|lXW0GQR1XS
RMG-I M1rWU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Lq[mlEPTB;MkmuOFE{QSEQvF2= M2r4[nNCVkeHUh?=
H9 NWH1WFM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S2WWlEPTB;M{GuN|AxQCEQvF2= M1XtZnNCVkeHUh?=
GR-ST MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HNeGlEPTB;M{KuOFQ2OyEQvF2= NXn1XWdFW0GQR1XS
Mo-T M4nuUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTN{LkWwOFYh|ryP MYHTRW5ITVJ?
SW1088 Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHtcHdKSzVyPUOyMlk5ODFizszN MWTTRW5ITVJ?
LB2518-MEL M3LLU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTN|LkC3PVch|ryP M13Ve3NCVkeHUh?=
NCI-H82 Ml3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTN|LkG2OlEh|ryP MXvTRW5ITVJ?
LAMA-84 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPRVpF7UUN3ME2zOE43ODd|IN88US=> NUX5XG5ZW0GQR1XS
KYSE-450 M{DO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHSb2lKSzVyPUO0MlY4PzZizszN MoiwV2FPT0WU
LU-99A NXu2Vm5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrVfm1KSzVyPUO1MlAxODdizszN NWPuZ2t{W0GQR1XS
BE-13 NG[4ZYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTN3Lk[1OFUh|ryP MVzTRW5ITVJ?
GAK MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTN3Lk[5OUDPxE1? NF73NIZUSU6JRWK=
NCI-H1573 NIL3OJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLpTWM2OD1|NT64PFE5KM7:TR?= NYTTZ3hZW0GQR1XS
AsPC-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TRO2lEPTB;M{[uNVUzPyEQvF2= MUPTRW5ITVJ?
HDLM-2 NYXYUpNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL3TZpKSzVyPUO2MlMyPiEQvF2= M3fvcXNCVkeHUh?=
NCI-H441 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjBd|ZKSzVyPUO3MlA3QTFizszN NXSySJJ6W0GQR1XS
CAL-27 MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[1TWM2OD1|Nz63NlMyKM7:TR?= MoXYV2FPT0WU
OVCAR-3 MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjLUWNKSzVyPUO5MlMyQDFizszN Mk\CV2FPT0WU
RPMI-8226 M4PReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHyOJh5UUN3ME2zPU42QThizszN MXjTRW5ITVJ?
EFO-21 M3G2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfiTWM2OD12MD61PFE1KM7:TR?= MmT5V2FPT0WU
SNU-C2B MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjIbXhGUUN3ME20NU42ODh2IN88US=> M{L5enNCVkeHUh?=
VM-CUB-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HiVmlEPTB;NEOuPFA{PyEQvF2= NULrZmQ4W0GQR1XS
NCI-H2087 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYmzcmNvUUN3ME20OU4xOjN|IN88US=> M1:2[HNCVkeHUh?=
EW-16 NVvBRmN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfkdGdFUUN3ME20Ok4{OTN5IN88US=> M3vhN3NCVkeHUh?=
SK-N-AS NWTjTZljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTR4LkexOlch|ryP MV3TRW5ITVJ?
COR-L105 MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTR4Lki4OVch|ryP M2PBd3NCVkeHUh?=
DEL NEHje2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHNUnJKSzVyPUS4MlA1OjlizszN NX;rN|Q5W0GQR1XS
JVM-2 MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHUTWM2OD12OD6wOVU5KM7:TR?= MnPOV2FPT0WU
KARPAS-45 NYizUIlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTR7LkS1N|gh|ryP MmTYV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / MDM2 / p21 / Bax / Bak / Noxa / cleaved caspase / pro-caspase; 

PubMed: 16014563     


Expression of apoptosis- and cell-cycle–associated proteins in OCI-AML-3 cells, which were treated with 5 μM Nutlin-3a for the indicated times. Nutlin-3a induced increased protein expression of p53, MDM2, and p21 in OCI-AML-3 cells in a time-dependent fashion. Nutlin-3a induced Noxa, a BH3-only member of the Bcl-2 family, followed by caspase activation. β-actin was used to confirm equal loading of proteins. Arrowheads indicate cleared caspases.

BMI-1; 

PubMed: 26887044     


Western blot analysis of BMI-1 and actin was performed in BV-173, SUP-B15, NALM-6, NALM-19 and REH cell lines after 24 hours treatment with increasing concentrations of Nutlin-3a (1 μM, 2 μM, 5 μM) and with DMSO control. 

p53-Ser15 / p53-Ser37 / p53-Lys382 / MDM2 / CDC2 / PLK1 / HSC70; 

PubMed: 23666059     


Expression of the indicated proteins in whole-cell lysates of cells treated for 96 h with 50 μM resveratrol (R), 5 μM nutlin-3a (N), or co-treated with both substances (RN).

16014563 26887044 23666059
Immunofluorescence
p-p21 / β-actin; 

PubMed: 31083332     


Cells were treated with fluoride (5 mM) with/without Nutlin-3a for 24 h. p-p21 (green), nucleus (DAPI; blue) and β-actin (red) expression were detected by immunocytochemistry. Nutlin-3a addition augmented p-p21 expression compared to NaF treatment alone.

P53; 

PubMed: 21394100     


At 12 h following treatment with nutlin-3a, DoHH2 and MCA cells had increased levels of p53 visualized by immunofluorescence. p53 localization was predominantly nuclear. The 4',6-diamidino-2-phenylindole was used as counterstain of the nuclei.

Ac-p300; 

PubMed: 30240745     


HepG2 cells were treated with 5 μM Nutlin-3a for 24 hr, and the levels of Ac-p300 and p53 were assessed by co-immunofluorescence. Fluorescence intensity of Ac-p300 in control cells versus Nutlin-3a-treated cells have been quantified (represented as mean ± SD, unpaired two-tailed Student's t test, n = 50 of three independent experiments). Scale bar, 10 μm.

31083332 21394100 30240745
Growth inhibition assay
Cell viability; 

PubMed: 26248031     


All 15 cell lines were plated in 96-well plates. After 24h, media was exchanged and cells were treated with incremental concentrations of Nutlin-3a (1 μM, 5 μM, 10 μM, 25 μM, 50 μM, and 70 μM). After 72h of Nutlin-3a treatment, cell viability was measured by WST assay and compared to untreated control.

26248031
In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
+ Expand

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
+ Expand
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: SJSA-1 xenograft
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+55% PEG 300+ddH2O
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
in solvent
Synonyms (-)-Nutlin-3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • Answer:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Mdm2 Signaling Pathway Map

Related Mdm2 Products0

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID